GlassScriptPhysician profile
Tomasz P Srokowski
NPI 1174671937
$852.32
in general payments reported to CMS, 2019-2025
16 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.14 · 2023: $12.85 · 2024: $82.27 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758 · Education: $61.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.88 |
| Education | $61.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $126.66 | 2024-2025 | |
| Daiichi Sankyo INC. | $120.90 | 2025 | Enhertu, Datroway |
| Abbvie INC. | $115.46 | 2024-2025 | |
| Pfizer INC. | $98.68 | 2025 | |
| Merck Sharp & Dohme LLC | $58.30 | 2025 | Keytruda, Keytruda Qlex, Welireg |
| Janssen Scientific Affairs, LLC | $47.63 | 2024-2025 | Darzalex, Rybrevant |
| Incyte Corporation | $43.01 | 2025 | Zynyz, Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $38.40 | 2025 | Enhertu, Lynparza |
| Janssen Biotech, INC. | $37.25 | 2025 | Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $33.14 | 2020 | |
| Caris Mpi, INC. | $29.00 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $27.63 | 2025 | Vyloy |
| Myriad Genetic Laboratories, INC. | $25.81 | 2025 | Myrisk |
| Exelixis INC. | $19.31 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $18.29 | 2025 | Libtayo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $12.85 | 2023 | Opdualag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomasz Srokowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.